TY - JOUR
T1 - Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line
AU - Agathangelidis, Andreas
AU - Scarfò, Lydia
AU - Barbaglio, Federica
AU - Apollonio, Benedetta
AU - Bertilaccio, Maria Teresa Sabrina
AU - Ranghetti, Pamela
AU - Ponzoni, Maurilio
AU - Leone, Gabriella
AU - De Pascali, Valeria
AU - Pecciarini, Lorenza
AU - Ghia, Paolo
AU - Caligaris-Cappio, Federico
AU - Scielzo, Cristina
N1 - Funding Information:
We thank the Lymphoid Malignancies Unit especially Elisa ten Hacken for helpful suggestions and technical support. This project was supported by: Associazione Italiana per la Ricerca sul Cancro AIRC (Investigator Grant and Special Program Molecular Clinical Oncology– 5 per mille #9965). AA is recipient of a fellowship by Associazione Italiana per la Ricerca sul Cancro AIRC (Triennial fellowship “Guglielmina Lucatello e Gino Mazzega”).
PY - 2015
Y1 - 2015
N2 - Immortalized cell lines representative of chronic lymphocytic leukemia (CLL) can assist in understanding disease pathogenesis and testing new therapeutic agents. At present, very few representative cell lines are available. We here describe the characterization of a new cell line (PCL12) that grew spontaneously from the peripheral blood (PB) of a CLL patient with progressive disease and EBV infection. The CLL cell origin of PCL12 was confirmed after the alignment of its IGH sequence against the "original" clonotypic sequence. The IGH gene rearrangement was truly unmutated and no CLL-related cytogenetic or genetic lesions were detected. PCL12 cells express CD19, CD20, CD5, CD23, low levels of IgM and IgD and the poor-outcome-associated prognostic markers CD38, ZAP70 and TCL1. In accordance with its aggressive phenotype the cell line is inactive in terms of LYN and HS1 phosphorylation. BcR signalling pathway is constitutively active and anergic in terms of p-ERK and Calcium flux response to α-IgM stimulation. PCL12 cells strongly migrate in vitro in response to SDF-1 and form clusters. Finally, they grow rapidly and localize in all lymphoid organs when xenotrasplanted in Rag2-/-γc-/- mice. PCL12 represents a suitable preclinical model for testing pharmacological agents.
AB - Immortalized cell lines representative of chronic lymphocytic leukemia (CLL) can assist in understanding disease pathogenesis and testing new therapeutic agents. At present, very few representative cell lines are available. We here describe the characterization of a new cell line (PCL12) that grew spontaneously from the peripheral blood (PB) of a CLL patient with progressive disease and EBV infection. The CLL cell origin of PCL12 was confirmed after the alignment of its IGH sequence against the "original" clonotypic sequence. The IGH gene rearrangement was truly unmutated and no CLL-related cytogenetic or genetic lesions were detected. PCL12 cells express CD19, CD20, CD5, CD23, low levels of IgM and IgD and the poor-outcome-associated prognostic markers CD38, ZAP70 and TCL1. In accordance with its aggressive phenotype the cell line is inactive in terms of LYN and HS1 phosphorylation. BcR signalling pathway is constitutively active and anergic in terms of p-ERK and Calcium flux response to α-IgM stimulation. PCL12 cells strongly migrate in vitro in response to SDF-1 and form clusters. Finally, they grow rapidly and localize in all lymphoid organs when xenotrasplanted in Rag2-/-γc-/- mice. PCL12 represents a suitable preclinical model for testing pharmacological agents.
UR - http://www.scopus.com/inward/record.url?scp=85018655979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018655979&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0130195
DO - 10.1371/journal.pone.0130195
M3 - Article
C2 - 26110819
AN - SCOPUS:85018655979
SN - 1932-6203
VL - 10
SP - e0130195
JO - PloS one
JF - PloS one
IS - 6
ER -